Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibit...
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients ≥12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Expanded Access for Relatlimab
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05170659
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT05034536
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
- Conditions
- Locally Advanced Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaStage IIIA Bladder Cancer AJCC v8Unresectable Ureter Urothelial CarcinomaUnresectable Urethral Urothelial CarcinomaUnresectable Urothelial CarcinomaLocally Advanced Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04953104
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 30
- Registration Number
- NCT04913922
- Locations
- 🇩🇪
University Hospital, LMU Munich, Munich, Germany
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 20
- Registration Number
- NCT04658147
- Locations
- 🇺🇸
The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 468
- Registration Number
- NCT04623775
- Locations
- 🇺🇸
Local Institution - 0147, Pittsburgh, Pennsylvania, United States
🇧🇪Local Institution - 0131, Ghent, Belgium
🇧🇪Local Institution - 0125, Roeselare, Belgium
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 5
- Registration Number
- NCT04611126
- Locations
- 🇩🇰
National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 266
- Registration Number
- NCT04567615
- Locations
- 🇧🇷
Local Institution - 0016, Barretos, SAO Paulo, Brazil
🇦🇷Local Institution - 0010, Ciudad de Buenos Aires, Buenos Aires, Argentina
🇦🇷Local Institution - 0019, Buenos Aires, Distrito Federal, Argentina
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jose Lutzky, MD
- Target Recruit Count
- 27
- Registration Number
- NCT04552223
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT04112498
- Locations
- 🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.